Protect Pharmaceutical Corporation (PRTT) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Protect Pharmaceutical Corporation $0.22, price $0.14, upside +53.7%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Protect Pharmaceutical Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0200 – $4.69 · fair‑value band $0.1414 – $0.3568 · the $0.1430 price screens below the $0.2198 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Protect Pharmaceutical in your weekly email
Every Wednesday you see whether Protect Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties.
Show more
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.
Stock analysis
Protect Pharmaceutical Corporation (PRTT) currently trades at $0.1430, while our model-based Fair Value estimate is $0.2198, implying the stock looks roughly 34.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.1099 per share, and 0 of the 7 models we run sit above the $0.1430 price.
Bear case: the Multiples group reads lowest at $0.0617, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1414 (bear) to $0.3568 (bull), the price of $0.1430 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Protect Pharmaceutical Corporation reported revenue of $132M in FY2024 versus $5.9M in FY2020, a compound +117.2%/yr. Reported net income was −$333M in FY2025.
Key figures
Market cap $8.2M · Return on assets (EBIT) 10.4% · Free cash flow $10.2M · Net cash $13.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and 615% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 13% fair-value upside, at 54%, PRTT screens cheaper than that median.
Fair Value models
Bear $0.1414Fair Value $0.2198Bull $0.3568
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
97.9% (2020) → 43.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Protect Pharmaceutical Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Integrated Freight & Logistics · 217 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Protect Pharmaceutical Corporation (PRTT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.2198 versus a price of $0.1430, about +54% upside (undervalued).
What is the fair value of PRTT?
Our model-based fair value for Protect Pharmaceutical Corporation is $0.2198 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.1430.
What is the quality score of PRTT?
Protect Pharmaceutical Corporation has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Protect Pharmaceutical Corporation (PRTT)?
Our model-based price target is the fair value of $0.2198 (as of Sep 23, 2026) from 7 valuation models. Cautious scenario $0.1414, optimistic scenario $0.3568. It is a calculation from audited fundamentals, not an analyst target.
What is the Protect Pharmaceutical Corporation stock forecast for 2026?
Our models put fair value at $0.2198, about +54% upside versus a price of $0.1430 (undervalued). Cautious scenario $0.1414, optimistic scenario $0.3568. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Protect Pharmaceutical Corporation (PRTT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Protect Pharmaceutical Corporation it is $0.2198 per share (as of Sep 23, 2026), against a price of $0.1430. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Protect Pharmaceutical Corporation stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PRTT trades below its calculated fair value: price $0.1430, fair value $0.2198, a gap of about +54% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRTT?
No. The price is what the market pays today ($0.1430); the fair value is what the company's own numbers justify ($0.2198). For Protect Pharmaceutical Corporation the two are $0.0768 per share apart. That gap is exactly why we show both numbers side by side.
How much is Protect Pharmaceutical Corporation worth?
The market values Protect Pharmaceutical Corporation at about $8.2M (market capitalisation, as of Sep 23, 2026). Per share that is $0.1430; our models calculate a fair value of $0.2198 per share.
What do the bullish and bearish scenarios say about PRTT?
Our models span a range for Protect Pharmaceutical Corporation: cautious scenario $0.1414, base $0.2198, optimistic $0.3568 per share (as of Sep 23, 2026, price $0.1430). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is PRTT from its 52-week high?
Protect Pharmaceutical Corporation trades at $0.1430, about 70% below its 52-week high of $0.4790 and 615% above the low of $0.0200 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2198 is for.
Which stocks are comparable to Protect Pharmaceutical Corporation?
From the same area (Industrials) we also value United Parcel Service, Inc, FedEx Corporation, Deutsche Post AG, DSV A/S, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Protect Pharmaceutical Corporation stock attractive at the current price?
The data as of Sep 23, 2026: price $0.1430, calculated fair value $0.2198 (+54%), Quality Score 43/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRTT calculated?
We run Protect Pharmaceutical Corporation through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2198, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Protect Pharmaceutical Corporation currently trades 54 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Protect Pharmaceutical Corporation (PRTT)?
The closing price on Sep 23, 2026 was $0.1430. Our model-based fair value is $0.2198, about +54% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Protect Pharmaceutical Corporation right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1414 to $0.3568) leaves room in how you read the outcome.
Key figures of Protect Pharmaceutical Corporation
How large is the market capitalisation of Protect Pharmaceutical Corporation (PRTT)?
The market capitalisation of Protect Pharmaceutical Corporation is $8.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the EBIT return on assets of Protect Pharmaceutical Corporation (PRTT)?
On an EBIT basis the return on assets of Protect Pharmaceutical Corporation is 10.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Protect Pharmaceutical Corporation (PRTT) generate?
The free cash flow of Protect Pharmaceutical Corporation is $10.2M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Protect Pharmaceutical Corporation (PRTT) hold?
Protect Pharmaceutical Corporation holds more cash than debt, $13.8M net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Protect Pharmaceutical Corporation in the live analysis
One click puts Protect Pharmaceutical Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026